Quantcast

Latest Emtricitabine Stories

2009-07-20 07:00:00

CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine). ARTEN is an open-label, multi-center and international non-inferiority clinical trial. It is the first large study to directly compare the efficacy and safety of nevirapine and ritonavir-boosted atazanavir (ATV/r) when combined with TDF/FTC, a...

2009-07-16 15:28:00

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for...

2009-03-30 15:34:00

PITTSBURGH, March 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg. Mylan Vice Chairman...

2008-11-01 12:00:15

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this...

2008-10-27 12:00:29

Bristol-Myers Squibb Company has announced positive 96-week data from the Castle study, in which 74% of the 440 patients in the Reyataz/r arm achieved an undetectable viral load, defined as HIV-1 RNA less than 50 copies/ml, compared with 68% of the 443 patients in the lopinavir/r arm. The difference between treatment arms may have been related to the 16% discontinuation rate in the Reyataz/r arm and the 21% discontinuation rate in the lopinavir/r arm, the company said. The international,...

2008-10-27 09:00:41

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that additional data from a Phase 2a monotherapy study of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of human immunodeficiency virus (HIV), were presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC. Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, gave an oral presentation showing that in the Phase 2a study, RDEA806...

2008-10-26 12:00:11

WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported a data analysis showing that vicriviroc, its investigational CCR5 receptor antagonist, demonstrated sustained viral suppression and increased CD4 cell counts and was well tolerated through up to four years of therapy in treatment-experienced HIV-infected patients. Vicriviroc was administered once-daily as a single tablet in combination with an optimized antiretroviral regimen containing a...

2008-10-22 09:00:10

BRIDGEWATER, N.J., Oct. 22 /PRNewswire/ -- The FDA has granted PREZISTA (darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults (those who have never taken HIV medication before). The FDA also granted traditional (full) approval to PREZISTA as twice-daily for use in treatment-experienced adult patients. PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by...

2008-08-14 03:00:47

Gilead Sciences has announced that the FDA has granted marketing approval for Viread for the treatment of chronic hepatitis B, a liver disease caused by the hepatitis B virus. Viread is now also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet, and works by blocking hepatitis B virus DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells. Viread has been available in the US as a treatment for HIV...

2008-08-08 09:01:34

Ardea Biosciences has presented positive data from its completed Phase IIa proof-of-concept monotherapy study of RDEA806, the company's investigational non-nucleoside reverse transcriptase inhibitor for patients with human immunodeficiency virus, demonstrating robust antiviral activity with a well-tolerated profile. The Phase IIa randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety and tolerability of once- and twice-daily oral dosing...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related